Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes

被引:24
作者
Li Yan [1 ]
Hao Ya-li [2 ]
Kang Shan [2 ]
Zhou Rong-miao [1 ]
Wang Na [1 ]
Qi Bing-li [2 ]
机构
[1] Hebei Med Univ, Hosp 4, Dept Mol Biol, Shijiazhuang 050011, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Obstet & Gynaecol, Shijiazhuang 050011, Peoples R China
关键词
Fas; FasL; Polymorphisms; Epithelial ovarian cancer; Risk; Clinical outcome; MOLECULAR-CLONING; APOPTOSIS; PROMOTER; EXPRESSION; LIGAND; CD95; CHEMOTHERAPY; CONTRIBUTE; MEMBER;
D O I
10.1016/j.ygyno.2012.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim. In this study, we evaluated whether functional polymorphisms within the Fas and FasL genes were associated with the risk of developing epithelial ovarian cancer (EOC) and survival of patients with EOC. Methods. A case-control study was performed in 342 EOC patients and 344 control women. The genotypes of three promoter region polymorphisms (Fas -1377G/A, -670A/G and FasL -844T/C) were determined using ligase detection reaction-polymerase chain reaction (LDR-PCR). The clinical outcomes in 202 EOC patients were compared across genotypes. Results. The genotype frequencies of the FasL -844 T/C polymorphism were significantly different between the case and control groups (P = 0.034). Compared to the T/T and T/C genotypes, the C/C genotype significantly increased the risk of developing EOC (OR = 1.46, 95% CI = 1.08-1.99). The survival analysis showed that the Fas -1377G/A and -670A/G polymorphisms were related to prognosis in EOC patients: Compared with patients with the G/G genotype of the -1377G/A polymorphism, patients carrying the A allele had a shorter PFS and OS, as determined by univariate and multivariate analysis (HR = 1.81, 95% CI = 1.26-2.62 and HR = 1.86, 95% CI = 1.15-3.00, respectively). Similarly, Kaplan-Meier and Cox proportional hazard model analyses indicated that patients carrying the G allele of Fas -670A/G polymorphisms had shorter PFS and OS than those carrying the AA genotype (HR = 1.67, 95% CI = 1.15-2.42 and HR = 1.80, 95% CI = 1.10-2.94, respectively). Conclusions. Functional polymorphisms in the Pus and FasL genes may be involved in epithelial ovarian cancer development and progression in northern Chinese women. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:584 / 589
页数:6
相关论文
共 33 条
[1]  
Anthoney DA, 1996, CANCER RES, V56, P1374
[2]   Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer [J].
Chaudhry, Parvesh ;
Srinivasan, Radhika ;
Patel, Firuza D. ;
Gopalan, Sarala ;
Majumdar, Siddhartha .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (08) :1716-1721
[3]   Expression of the Major Fas Family and Bcl-2 Family of Proteins in Epithelial Ovarian Cancer (EOC) and Their Correlation to Chemotherapeutic Response and Outcome [J].
Chaudhry, Parvesh ;
Srinivasan, Radhika ;
Patel, Firuza D. .
ONCOLOGY RESEARCH, 2010, 18 (11-12) :549-559
[4]   Gene expression profiles of pancreatic cancer and stromal desmoplasia [J].
Crnogorac-Jurcevic, T ;
Efthimiou, E ;
Capelli, P ;
Blaveri, E ;
Baron, A ;
Terris, B ;
Jones, M ;
Tyson, K ;
Bassi, C ;
Scarpa, A ;
Lemoine, NR .
ONCOGENE, 2001, 20 (50) :7437-7446
[5]   The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer [J].
Duiker, Evelien W. ;
van der Zee, Ate G. J. ;
de Graeff, Pauline ;
Boersma-van Ek, Wytsle ;
Hollema, Harry ;
de Bock, Geertruida H. ;
de Jong, Steven ;
de Vries, Elisabeth G. E. .
GYNECOLOGIC ONCOLOGY, 2010, 116 (03) :549-555
[6]   Proliferation, cell cycle and apoptosis in cancer [J].
Evan, GI ;
Vousden, KH .
NATURE, 2001, 411 (6835) :342-348
[7]   Chemoresistance in human ovarian cancer: The role of apoptotic regulators [J].
Michael Fraser ;
Brendan Leung ;
Arezu Jahani-Asl ;
Xiaojuan Yan ;
Winston E Thompson ;
Benjamin K Tsang .
Reproductive Biology and Endocrinology, 1 (1)
[8]  
Gormus U, 2007, ANTICANCER RES, V27, P991
[9]   Apoptosome dysfunction in human cancer [J].
Hajra, KM ;
Liu, JR .
APOPTOSIS, 2004, 9 (06) :691-704
[10]   CHEMOTHERAPY-INDUCED APOPTOSIS IN EPITHELIAL OVARIAN CANCERS [J].
HAVRILESKY, LJ ;
ELBENDARY, A ;
HURTEAU, JA ;
WHITAKER, RS ;
RODRIGUEZ, GC ;
BERCHUCK, A .
OBSTETRICS AND GYNECOLOGY, 1995, 85 (06) :1007-1010